Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.
Kevin J HarringtonBarbara A BurtnessRichard GreilDenis SoulieresMakato TaharaGilberto de Castro JuniorAmanda PsyrriIrene BranaNeus BastéPrakash NeupaneÅse BratlandThorsten FuerederBrett G M HughesRicard MesíaNuttapong NgamphaiboonTamara RordorfWan Zamaniah Wan IshakJianxin LinBurak GumuscuRamona F SwabyDanny RischinPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
With a 4-year follow-up, first-line pembrolizumab and pembrolizumab-chemotherapy continued to demonstrate survival benefit versus cetuximab-chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma. Patients responded well to subsequent treatment after pembrolizumab-based therapy.
Keyphrases
- locally advanced
- advanced non small cell lung cancer
- phase iii
- squamous cell carcinoma
- end stage renal disease
- small cell lung cancer
- ejection fraction
- clinical trial
- open label
- chronic kidney disease
- phase ii
- newly diagnosed
- rectal cancer
- peritoneal dialysis
- radiation therapy
- stem cells
- epidermal growth factor receptor
- chemotherapy induced
- patient reported outcomes
- double blind
- mesenchymal stem cells
- bone marrow
- replacement therapy
- study protocol
- combination therapy
- tyrosine kinase